| Latest Schering Plough News Headlines |
| Date | Time | Source | |
| 11/24/2008 | 1:01PM | PRNUS | Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Leaders of Schering-Plough Corporation (NYSE:SGP) today provided an update for investors on the company's research pipeline, highlighting a rich and innovative portfolio that includes 46 new entities in clinical trials or under regulatory review and 29 in preclinical... More...>> |
| 11/24/2008 | 11:21AM | PRNUS | Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhib
Company reaffirms its innovation leadership and long-term commitment to hepatitis research
KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development... More...>> |
| 11/24/2008 | 10:35AM | PRNUS | Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Rel
Company's R&D Update Today Unveils Rich Development Pipeline of Compounds Meeting Important Medical Needs
KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today revealed top-line results of a long-term Phase III clinical study of its psychopharmacologic agent SAPHRIS(TM) (asenapine... More...>> |
| 11/24/2008 | 10:35AM | PRNUS | Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease experiencing... More...>> |
| 11/11/2008 | 9:31AM | PRNUS | Seven Summits Research Releases Alerts on RIMM, JPM, SGP, BG, and MR
CHICAGO, Nov. 11 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks.
Seven Summits Strategic Investments' PriceWatch Alerts are available at
http://www.iotogo.com/s/111108A (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's PriceWatch Alerts cover... More...>> |
| 11/07/2008 | 11:58AM | PRNUS | Schering-Plough to Webcast R&D Update Meeting
KENILWORTH, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) will webcast its "R&D Update" meeting for analysts and portfolio managers being held on Monday, Nov. 24, 2008. Fred Hassan, Schering-Plough's chairman and CEO, Tom Koestler, Ph.D., executive vice president and president, Schering-Plough... More...>> |
| 11/01/2008 | 11:00AM | PRNUS | Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hep
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting
SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported that a planned interim analysis of a Phase II study showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination... More...>> |
| 10/30/2008 | 5:29PM | PRNUS | Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case
ST. LOUIS, Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) said today that it strongly believes that the decision reached by a jury in Missouri related to reimbursement by Missouri's Medicaid program of certain products sold by Warrick Pharmaceuticals, the company's former generics subsidiary... More...>> |
| 10/30/2008 | 5:29PM | PRNUS | Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case
ST. LOUIS, Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) said today that it strongly believes that the decision reached by a jury in Missouri related to reimbursement by Missouri's Medicaid program of certain products sold by Warrick Pharmaceuticals, the company's former generics subsidiary... More...>> |
| 10/28/2008 | 8:30AM | PRNUS | Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
Publication of Comparative Study Shows Sugammadex Provides Significantly Faster Reversal of Profound Rocuronium-Induced Muscle Relaxation than Neostigmine
KENILWORTH, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE:SGP) today announced that a study published in the November 2008 issue of the medical... More...>> |
| 10/26/2008 | 11:15AM | PRNUS | Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerabili
Data Analysis of Up to Four Years of Treatment Presented at ICAAC/IDSA 2008 Annual Meeting
WASHINGTON, Oct. 26 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported a data analysis showing that vicriviroc, its investigational CCR5 receptor antagonist, demonstrated sustained viral suppression... More...>> |
| 10/23/2008 | 1:23PM | PRNUS | Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
KENILWORTH, N.J., Oct. 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that its novel psychopharmacologic agent asenapine has met the primary endpoint in a long-term schizophrenia relapse prevention trial. Asenapine, which is administered as a fast-dissolving sublingual tablet, is... More...>> |
| 10/21/2008 | 6:47AM | PRNUS | Schering-Plough Reports Financial Results for Third Quarter of 2008
Strong Financial Performance Driven By Strength and Diversity on Many Fronts; Productivity Transformation Taking Hold
KENILWORTH, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported financial results for the third quarter of 2008.
"Our performance this quarter again demonstrates... More...>> |
| 10/20/2008 | 9:31AM | PRNUS | Seven Summits Research Releases Alerts on JPM, CAT, AMR, SYMC, and SGP
CHICAGO, Oct. 20 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for key stocks.
Seven Summits Strategic Investments' PriceWatch Alerts are available at
http://www.iotogo.com/s/102008A (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's PriceWatch Alerts cover... More...>> |
| 10/17/2008 | 11:47AM | PRNUS | Schering-Plough Announces Transition of Animal Health Leadership
KENILWORTH, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced the transition of leadership of its Animal Health unit from Ruurd Stolp, D.V.M., Ph.D., to Raul E. Kohan, who was previously the Deputy Head of the Animal Health unit. In his role as senior vice president and... More...>> |
| 09/23/2008 | 4:30PM | PRNUS | Schering-Plough Schedules Conference Call and Webcast for 2008 Third Quarter Earnings
KENILWORTH, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) is scheduled to announce its sales and earnings results for the 2008 third quarter on Tuesday, Oct. 21, 2008.
At 8 a.m. (EDT) on that day, Schering-Plough will conduct a conference call to review results for the 2008 third quarter... More...>> |
| 09/23/2008 | 1:00PM | PRNUS | U.S. Pet Owners can Double the Impact of Vaccinations to Help Reduce Rabies in Africa, Save Lives
'Help Here. Change There.' Theme of Vaccination Campaign
MILLSBORO, Del., Sept. 23 /PRNewswire/ -- American pet owners and their animals can help save lives in Africa through vaccinations administered in the U.S. between now and December 31, 2008. Pet owners are invited to double the impact of the annual veterinary... More...>> |
| 09/16/2008 | 11:42AM | PRNUS | Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
KENILWORTH, N.J., Sept. 16 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE:SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Nov. 25, 2008, to shareholders of record at the close of business on Nov. 7, 2008. As of June 30, 2008, there... More...>> |
| 09/10/2008 | 5:31PM | PRNUS | Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products to Pfizer
KENILWORTH, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced the successful closing of its previously announced transaction with Pfizer Animal Health, to divest certain animal health products from selected franchises in the European Economic Area to Pfizer. These divestments... More...>> |
| 09/10/2008 | 2:57PM | PRNUS | Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
First product launch following acquisition of Organon BioSciences
KENILWORTH, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that the European launch of BRIDION(R) (sugammadex) injection has begun with its introduction this week in Sweden, and that the product is expected... More...>> |